Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06210776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06210776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Recruiting
Start date
January 15, 2024
Completion date
March 1, 2028
Enrollment
800 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, breast cancer, her2-low breast cancer, her2-positive breast cancer